RAPT Therapeutics to be Acquired by GSK for $2.2 Billion in All-Cash Tender Offer at $58.00 Per Share

summarizeSummary

RAPT Therapeutics has agreed to be acquired by GlaxoSmithKline for approximately $2.2 billion, with shareholders receiving $58.00 per share in cash, representing a significant premium.

check_boxKey Events

• Acquisition Agreement

  RAPT Therapeutics has entered into a definitive agreement to be acquired by GlaxoSmithKline LLC (GSK) for approximately $2.2 billion.

• Tender Offer Price

  GSK will commence a tender offer to purchase all outstanding shares of RAPT common stock at a price of $58.00 per share in cash.

• Significant Premium

  The offer price represents a 65% premium to the last closing price (January 16, 2026) and a 37% premium to the 52-week high of RAPT shares.

• Strategic Rationale

  The acquisition is expected to accelerate the development of RAPT's programs, particularly ozureprubart in food allergy, leveraging GSK's global resources.

auto_awesomeAnalysis

The definitive agreement for GlaxoSmithKline to acquire RAPT Therapeutics at a substantial premium fundamentally alters the investment thesis, providing immediate and significant value to shareholders. The $2.2 billion all-cash deal represents a 65% premium over RAPT's last closing price and a 37% premium over its 52-week high, reflecting strong confidence in RAPT's pipeline, particularly ozureprubart. This strategic acquisition by a major pharmaceutical company ensures RAPT's programs will benefit from extensive resources and infrastructure, de-risking future development and commercialization. Investors should expect the stock price to converge towards the $58.00 offer price, with the transaction anticipated to close in the first quarter of 2026.